Opus Genetics, Inc.
- IRD
- NASDAQ
- Biotechnology
- Ophthalmology Biopharma
- Retinal Disease Therapies
$3.82
Today −0.52%Quote Oct 19, 2026, 08:00 PM UTC
−27.27%over the last month
Max drawdown −27.3%From 1-month high −27.3%3 months +25.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Opus Genetics
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
28
Founded
2018
Market value
$317.8M
Quote Oct 19
Floor
$3.75
1.9% below price
Resistance
$3.96
3.8% above price
Price vs analyst targets
9 analysts
Lowest target
$8.00Highest target
$20.00
$8.00Highest target
$20.00
- Price $3.82
- Average target $12.60
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 230% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about IRDPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free